Female Sexual Dysfunction

Get Email Updates

Female Sexual Dysfunction Guide

Susan Cody HERWriter Guide

Have a question? We're here to help. Ask the Community.

ASK

Free Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER!

How the Latest “Pink Pill” Studies Tested Women’s Sex Drive--and Failed

By EmpowHER June 18, 2010 - 10:35am
 
Rate This
0 comments View Comments

It’s all but official. Hopes have been dashed, once again, for a “pink pill” that can boost low sex drive in females as quickly as the popular “blue pill” Viagra pumps up sex organs in males.

The German pharmaceutical company Boehringer Ingelheim recently released results from two large studies of pre-menopausal women who were treated for diminished sex drive with the drug flibanserin.

In a word, flibanserin flopped--at least in improving libido in most women tested. More studies are underway, but these recent results reconfirm that female sexuality is complicated and may not easily lend itself to a single pharmaceutical product.

Specifics on how the clinical trials were organized and what the results showed were made public this week in a large summary document from the Food and Drug Administration (FDA). See highlights of the study details and results below.

This information, plus the testimony from many experts in women’s health and female sexual dysfunction, will help a panel of analysts decide if flibanserin should be recommended for marketing to the public.

Details of the studies:
More than 1,200 pre-menopausal U.S. and Canadian women in long-term monogamous relationships received flibanserin in two double blind clinical experiments. A double blind study means neither the volunteer in the study nor the administrator knows which pill a volunteer receives—the real drug or a placebo pill-- until the end of the study. This keeps the volunteers and researchers from being swayed by their expectations for a positive or negative outcome while the study is underway. Four doses of flibanserin were tested in the treatment groups of women: 25 milligrams, twice per day; 50 milligrams, once per day; 50 milligrams, twice per day; and 100 milligrams, once per day.

The major goals of the two clinical trials were to examine safety and efficacy of flibanserin, standard objectives for what are called “phase III” clinical trials. Researchers looked at how well flibanserin improved the sexual activity and desire in the volunteers and also determined if any side effects occurred and how often.

 
Rate This
0 comments View Comments

We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Image CAPTCHA
By hitting submit, you agree to EmpowHER's terms of service and privacy policy

Improved

620 Health

Changed

294 Lives

Saved

211 Lives
1 lives impacted in the last 24 hrs Learn More

Take our Featured Poll

Do you think medical companies should continue to search for a "female Viagra" in the hopes of one day receiving FDA approval?:
View Results